Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: A case-control observational study of 27 recent cases

Journal of Infectious Diseases

Volumn 191, Issue 8, 2005, Pages 1350-1360

  Kontoyiannis, Dimitrios P ^a,b   Lionakis, Michail S ^a   Lewis, Russell E ^a,b   Chamilos, Georgios ^a   Healy, Mimi ^c   Perego, Cheryl ^a   Safdar, Amar ^a   Kantarjian, Hagop ^a   Champlin, Richard ^a   Walsh, Thomas J ^d   Raad, Issam I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c Spectral Genomics Inc   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICOSTEROID; ITRACONAZOLE; VORICONAZOLE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIBIOTIC SENSITIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CONTROLLED STUDY; DIABETES MELLITUS; FUNGUS ISOLATION; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; IN VITRO STUDY; INFECTION PREVENTION; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MOLECULAR TYPING; MUCORMYCOSIS; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECIPIENT; RHIZOPUS; RISK FACTOR; SINUSITIS; ZYGOMYCETES;

ANTIFUNGAL AGENTS; APACHE; ASPERGILLOSIS; ASPERGILLUS; CASE-CONTROL STUDIES; DNA FINGERPRINTING; DRUG RESISTANCE, FUNGAL; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS; ZYGOMYCOSIS;

EID: 20144389423     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/428780     Document Type: Article

References (40)

1. Marty EM, Cosimi L, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem cell transplants. N Engl J Med 2004; 350:950-2.
2. Siwek GT, Dodgson KJ, De Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39:584-7.
3. Imhof A, Balajee AS, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant patients receiving voriconazole. Clin Infect Dis 2004; 39:743-6.
4. Kaufman C. Zygomycosis: re-emergence of an old pathogen. Clin Infect Dis 2004; 39:588-90.
5. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225-34.
6. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
7. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34:563-71.
8. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21:240-8.
9. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122-31.
10. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44:343-500.
11. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003; 51:45-52.
12. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KVI. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30:851-6.
13. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-17.
14. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13:236-301.
15. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
16. Raad I, Hanna H, Osting C, et al. Masking of neutropenic patients on transport from hospital rooms is associated with a decrease in nosocomial aspergillosis during construction. Infect Control Hosp Epidemiol 2002; 23:41-3.
17. Larone DH. Medically important fungi: a guide to identification. 3rd ed. Washington, DC: ASM Press, 1995.
18. Richardson MD, Koukila-Kahlola P, Shankland GS. Rhizopus, Rhizomucor, Absidia, and other agents of systemic and subcutaneous Zygomycoses. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, eds. Manual of clinical microbiology. 8th ed. Washington, DC: ASM Press, 2003:1761-80.
19. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi: approved standard M38-A. Wayne, PA: NCCLS, 2002.
20. Kurtz MB, Heath IB, Marrinan J, Dreikorn S, Onishi J, Douglas C. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob Agents Chemother 1994; 38:1480-9.
21. Espinel-Ingroff A, Rezusta A. E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method. J Clin Microbiol 2002; 40:2101-7.
22. Espinel-Ingroff A, Fothergill A, Peter J, Rinaldi MG, Walsh TJ. Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol 2002; 40:3204-8.
23. White TJ, Bruns T, Lee S, Taylor JW. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, eds. PCR protocols: a guide to methods and applications. San Diego, CA: Academic Press, 1990:315-22.
24. Chakrabarti A, Ghosh A, Prasad GS, et al. Apophysomyces elegans: an emerging zygomycete in India. J Clin Microbiol 2003; 41:783-8.
25. Healy M, Reece K, Walton D, Huong J, Shah K, Kontoyiannis DP. Identification to the species level and differentiation between strains of Aspergillus clinical isolates by automated repetitive-sequence-based PCR. J Clin Microbiol 2004; 42:4016-24.
26. Sugar AM. Agents of mucormycosis and related species. In: Mandel GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 5th ed. Vol. 2. Philadelphia: Churchill Livingstone, 2000:2685-95.
27. Parfrey NA. Improved diagnosis and prognosis of mucormycosis: a clinicopathologic study of 33 cases. Medicine 1986; 65:113-23.
28. Pagano L, Ricci P, Tonso A, et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. Br J Haematol 1997; 99:331-6.
29. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 2002; 21:161-72.
30. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 2003; 362:1828-38.
31. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet 2002; 359:1135-44.
32. Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001; 32:1055-61.
33. Olive DM, Bean P. Principles and applications of methods for DNA-based typing of microbial organisms. J Clin Microbiol 1999; 37:1661-9.
34. Pfaller MA, Messer SA, Hollis RJ, Jones RN, SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46:1032-7.
35. Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999; 24:307-12.
36. Singh N. Trends in epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001; 33:1692-6.
37. Erjavec Z, Verweij PE. Recent progress in the diagnosis of fungal infections in the immunocompromised host. Drug Resist Updat 2002; 5:3-10.
38. Stevens DA. Diagnosis of fungal infections: current status. J Antimicrob Chemother 2002;49(Suppl S1):11-19.
39. Walsh TJ, Hiemenz JW, Seibel N, et al. Amphotericin B lipid complex in patients with invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26:1383-96.
40. Greenberg RN, Anstead G, Herbrecht R, et al. Posaconazole experience in the treatment of zygomycosis [abstract M-1757]. In: Program and abstracts of the 43th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago), 2003:476.